Joel Greenblatt’s EXAS Holdings & Trades

First Buy
Q2 2016
Duration Held
38 Quarters
Largest Add
Q3 2017
+154,834 Shares
Current Position
11,430 Shares
$625,335 Value

Joel Greenblatt's EXAS Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 11,430 shares of Exact Sciences Corporation (EXAS) worth $625,335, representing 0.00% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 38 quarters.

Based on 13F filings, Joel Greenblatt has maintained a strategic position in EXAS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2017, adding 154,834 shares. Largest reduction occurred in Q4 2017, reducing 121,882 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Exact Sciences Corporation (EXAS) Holding Value Over Time

Track share changes against reported price movement

Quarterly Exact Sciences Corporation (EXAS) Trades by Joel Greenblatt

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2016 +17,669 New Buy 17,669 $12.22
Q3 2016 +35,583 Add 201.39% 53,252 $18.57
Q4 2016 -53,252 Sold Out 53,252 $0.00
Q1 2017 +56,048 New Buy 56,048 $23.62
Q2 2017 +126,037 Add 224.87% 182,085 $35.37
Q3 2017 +154,834 Add 85.03% 336,919 $47.12
Q4 2017 -121,882 Reduce 36.18% 215,037 $52.54
Q1 2018 -86,423 Reduce 40.19% 128,614 $40.33
Q2 2018 -36,472 Reduce 28.36% 92,142 $59.79
Q3 2018 -48,316 Reduce 52.44% 43,826 $78.93
Q4 2018 +221 Add 0.50% 44,047 $63.09
Q1 2019 +944 Add 2.14% 44,991 $86.62
Q2 2019 -41,400 Reduce 92.02% 3,591 $118.07
Q3 2019 -3,591 Sold Out 3,591 $0.00
Q4 2019 +6,005 New Buy 6,005 $92.42
Q1 2020 +2,099 Add 34.95% 8,104 $58.00
Q2 2020 +9 Add 0.11% 8,113 $86.90
Q3 2020 -1,250 Reduce 15.41% 6,863 $102.00
Q4 2020 -1,027 Reduce 14.96% 5,836 $132.45
Q1 2021 -1,134 Reduce 19.43% 4,702 $131.86
Q2 2021 +33 Add 0.70% 4,735 $124.39
Q3 2021 +1,940 Add 40.97% 6,675 $95.43
Q4 2021 +1,815 Add 27.19% 8,490 $77.86
Q1 2022 -2,398 Reduce 28.24% 6,092 $69.93
Q2 2022 -6,092 Sold Out 6,092 $0.00
Q3 2022 +34,861 New Buy 34,861 $32.50
Q4 2022 +46,059 Add 132.12% 80,920 $49.51
Q1 2023 -2,086 Reduce 2.58% 78,834 $67.81
Q2 2023 +11,100 Add 14.08% 89,934 $93.90
Q3 2023 +4,347 Add 4.83% 94,281 $68.22
Q4 2023 -27,822 Reduce 29.51% 66,459 $73.98
Q1 2024 +8,650 Add 13.02% 75,109 $69.06
Q2 2024 +56,440 Add 75.14% 131,549 $42.25
Q3 2024 +30,873 Add 23.47% 162,422 $68.12
Q4 2024 -12,302 Reduce 7.57% 150,120 $56.19
Q1 2025 -73,541 Reduce 48.99% 76,579 $43.29
Q2 2025 +32,361 Add 42.26% 108,940 $53.14
Q3 2025 -97,510 Reduce 89.51% 11,430 $54.71

Joel Greenblatt's Exact Sciences Corporation Investment FAQs

Joel Greenblatt first purchased Exact Sciences Corporation (EXAS) in Q2 2016, acquiring 17,669 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Exact Sciences Corporation (EXAS) for 38 quarters since Q2 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt's largest addition to Exact Sciences Corporation (EXAS) was in Q3 2017, adding 336,919 shares worth $15.88 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 11,430 shares of Exact Sciences Corporation (EXAS), valued at approximately $625,335. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Exact Sciences Corporation (EXAS) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt's peak holding in Exact Sciences Corporation (EXAS) was 336,919 shares, as reported at the end of Q3 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.